AtriCure, Inc. $ATRC Shares Sold by Rhumbline Advisers

Rhumbline Advisers lessened its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 10.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 70,919 shares of the medical device company’s stock after selling 7,896 shares during the quarter. Rhumbline Advisers owned about 0.14% of AtriCure worth $2,288,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Ameriprise Financial Inc. purchased a new stake in shares of AtriCure during the 4th quarter valued at approximately $295,000. Envestnet Asset Management Inc. raised its position in shares of AtriCure by 22.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 56,656 shares of the medical device company’s stock valued at $1,828,000 after buying an additional 10,570 shares during the period. Acadian Asset Management LLC raised its position in shares of AtriCure by 2,690.0% during the 1st quarter. Acadian Asset Management LLC now owns 195,582 shares of the medical device company’s stock valued at $6,304,000 after buying an additional 188,572 shares during the period. Assenagon Asset Management S.A. raised its position in AtriCure by 5.0% in the first quarter. Assenagon Asset Management S.A. now owns 146,096 shares of the medical device company’s stock valued at $4,713,000 after purchasing an additional 6,995 shares during the period. Finally, GAMMA Investing LLC raised its position in AtriCure by 9,664.9% in the first quarter. GAMMA Investing LLC now owns 3,613 shares of the medical device company’s stock valued at $112,000 after purchasing an additional 3,576 shares during the period. Hedge funds and other institutional investors own 99.11% of the company’s stock.

Analyst Ratings Changes

ATRC has been the topic of a number of research analyst reports. Needham & Company LLC boosted their target price on AtriCure from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, July 30th. BTIG Research set a $54.00 target price on AtriCure in a research report on Wednesday, July 30th. Finally, Wall Street Zen raised AtriCure from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Nine equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $50.89.

Insider Buying and Selling at AtriCure

In other news, Director Regina E. Groves sold 2,452 shares of the company’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $36.82, for a total value of $90,282.64. Following the completion of the sale, the director directly owned 33,715 shares of the company’s stock, valued at approximately $1,241,386.30. This represents a 6.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Vinayak Doraiswamy sold 2,500 shares of the company’s stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $36.58, for a total transaction of $91,450.00. Following the completion of the sale, the insider directly owned 71,872 shares of the company’s stock, valued at $2,629,077.76. The trade was a 3.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 17,952 shares of company stock valued at $655,633 over the last ninety days. 3.50% of the stock is currently owned by corporate insiders.

AtriCure Stock Performance

NASDAQ:ATRC opened at $35.01 on Thursday. The company has a fifty day simple moving average of $34.56 and a two-hundred day simple moving average of $33.45. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -45.47 and a beta of 1.62. The company has a quick ratio of 2.83, a current ratio of 3.94 and a debt-to-equity ratio of 0.16. AtriCure, Inc. has a 52 week low of $25.57 and a 52 week high of $43.11.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Tuesday, July 29th. The medical device company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.13. AtriCure had a negative net margin of 7.27% and a negative return on equity of 4.20%. The firm had revenue of $136.14 million during the quarter, compared to the consensus estimate of $130.17 million. During the same quarter in the previous year, the firm posted ($0.17) earnings per share. The company’s revenue was up 17.1% compared to the same quarter last year. AtriCure has set its FY 2025 guidance at -0.390–0.340 EPS. As a group, equities analysts anticipate that AtriCure, Inc. will post -0.6 earnings per share for the current fiscal year.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.